In a nutshell
Da Volterra is a clinical-stage biopharmaceutical company which innovates for better health and care for people worldwide.
Our team is composed of 35 people with an extensive experience in science and in the industrial development of medical products. Together, we are dedicated to developing novel and safe therapeutic options for patients.
Our expertise focuses on the protection of the intestinal microbiota during antibiotic treatments.
- Based in Paris,
- 35 collaborators,
- Total funds raised since
- 1 product in phase 2
Da Volterra’s goal is to develop and commercialize innovative healthcare solutions to preserve the intestinal microbiota of patients worldwide and help prevent and cure life-threatening diseases.
As new insights into the human intestinal microbiota are fundamentally reshaping how we understand and treat a wide range of diseases, Da Volterra is a pioneer in understanding and harnessing the microbiota capacity to help prevent and cure diseases.
The company’s most advanced product is DAV132, an oral product to be co-administered with any antibiotics, in order to protect patients from antibiotic-induced intestinal microbiota disruption.